Search

Displaying results 4781 - 4790 of 10000 in total
  1. Drug

    Dihydrofolic Acid

    go.drugbank.com/drugs/DB02015
    Investigational

    Mixtures: EnLyte Extra-LN
  2. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  3. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  4. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  5. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports. … 19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo.

  6. Drug

    Methyl salicylate 2-ethylbutyrate

    go.drugbank.com/drugs/DB14130
    Investigational

    Mixtures: Thera Derm Roll On
  7. Drug

    Epigallocatechin gallate

    go.drugbank.com/drugs/DB12116
    Investigational

    Epigallocatechin gallate has been investigated for the treatment of Hypertension and Diabetic Nephropathy.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Therapeutic options to improve exercise performance in these patients are limited … It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment.

  9. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  10. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.